JOINN News

Zhaoyan New Pharmaceutical (603127): Gross margin is under pressure in the short term, production capacity and internationalization are progressing steadily

gtjaNov 3 17:52

Zhaoyan Pharmaceutical (603127): Short-term performance under pressure, core business picks up

國信證券Sep 13 16:21

Nomura Adjusts Joinn Laboratories (China)'s Price Target to 12.60 Yuan From 12.27 Yuan, Keeps at Neutral

MT NewswiresSep 3 17:09

JOINN LABORATORIES(6127.HK):PERFORMANCE UNDER PRESSURE DUE TO SHRINKING DOMESTIC DEMAND;DOWNGRADE TO HOLD

Sep 3 14:51

JOINN LABORATORIES(6127.HK):SIGNALS OF DEMAND RECOVERY IN 2Q24

Sep 2 19:41

Maintaining Buy Rating: JOINN Laboratories' Turnaround and Expansion Signal Strong Growth Potential

TipRanksSep 2 15:49

Zhaoyan New Pharmaceutical (603127): Significant month-on-month improvement project experience and quality system to maintain leadership

Sep 2 00:00

Nomura Adjusts Joinn Laboratories' Price Target to 12.27 Yuan From 17.37 Yuan, Keeps at Neutral

MT NewswiresJul 11 15:20

JOINN LABORATORIES(6127.HK):WAITING LONGER FOR RECOVERY TO MATERIALIZE

招银国际May 2 13:01

Nomura Adjusts Joinn Laboratories' Price Target to HK$10.41 From HK$12.60, Keeps at Neutral

MT NewswiresApr 30 17:42

Guoxin Securities released a research report on April 15 stating that it gave Zhaoyan New Pharmaceutical (603127.SH) a purchase rating. The main reasons for the rating include: 1) revenue is basically flat throughout the year, and the profit side is under

Zhitong FinanceApr 15 17:17

Zhaoyan New Pharmaceutical (603127): Revenue was basically flat for the full year of 2023, and the results of the internationalization strategy showed results

Apr 15 16:11

Bank Rating | Lyon: Upgraded Tiger Pharmaceuticals and Zhaoyan New Drug Ratings Benefit from Innovative Drug Support Policies

Gelonghui FinanceApr 11 13:35

Zhaoyan Pharmaceutical (603127) 2023 Annual Report Review: Profitability Under Short-term Pressure, Internationalization Continues to Advance

Apr 9 18:18

Zhaoyan New Pharmaceutical (603127): Profitability under short-term pressure, internationalization continues to advance

Apr 9 11:01

Zhaoyan Pharmaceutical (603127): Changes in biological asset value affect profits and await gradual recovery in 2024

Apr 7 00:00

Zhaoyan Pharmaceutical (6127.HK): It will take time for terminal demand to recover, and 2024 will still face challenges

Apr 3 00:00

Zhaoyan Pharmaceutical (603127): High overseas growth, local economy waiting for recovery

Apr 2 00:00

Zhaoyan Pharmaceutical (603127) 2023 Annual Report Review: Multiple Factors Influence Profits and Rapid Overseas Business Development

Mar 31 19:56

Zhaoyan Pharmaceutical (603127): Domestic business is under short-term pressure, and overseas revenue is growing steadily

Mar 31 00:00